A study on medication compliance of Pentasa granules in patients with inflammatory bowel disease

A study on medication compliance of Pentasa granules in patients with inflammatory bowel disease - A study on medication compliance of Pentasa granules

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000036049

Enrollment

Registered

2019-03-01

Start date

2017-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

inflammatory bowel disease

Interventions

Pentasa tablets (1-2 months) Pentasa granules (1-2 months)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inflammatory bowel disease patients who are medicated by Pentasa tablets

Exclusion criteria

Exclusion criteria: Physicians exclude the patients who is inappropriate for registration to this study due to high disease activity

Design outcomes

Primary

Measure	Time frame
Evaluation of medication compliance at switching to Pentasa granules from Pentas tablets in patients with inflammatory bowel disease	—

Secondary

Measure	Time frame
The aim of this study is to evaluate safety and disease activity at switching to Pentasa granules from Pentas tablets in patients with inflammatory bowel disease	—

Countries

Japan

Contacts

Public ContactShunji Ishihara

Shimane University Faculty of Medicine Internal Medicine II

si360405@med.shimane-u.ac.jp0853-20-2190

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026